Lhasa Limited shared knowledge shared progress

Lhasa Carcinogenicity Database

The Lhasa Carcinogenicity Database has been founded on the Carcinogenic Potency Database (CPDB), a widely used, free resource which contains the results of animal cancer tests. Lhasa Limited has used its knowledge in the field of user experience to add new functionality, building on the excellent work of the team behind the original database.

 

Carc DB Button 300px

Insight

Lhasa Carcinogenicity Data

Lhasa TD50

The Future

Features and Benefits

Key References

Insight

The original CPDB is an invaluable resource containing the results of 6,529 chronic, long-term animal cancer studies on 1,547 chemicals. Unfortunately, there is currently no guarantee that this database will remain available in the future, especially since the untimely passing of Dr. Lois Swirsky Gold, the Director of the CPDB project.

As a consequence of the potential risk of losing such a valuable resource, Lhasa Limited has adopted the database to continue the public benefit that it offers. This will ensure that the database will continue to be freely available to the public and will have new features and enhancements that provide an improved experience for the end user.

 

           

Lhasa Carcinogenicity Data

The Lhasa Carcinogenicity Database uses the same data and information as the original CPDB. However in some cases, after careful validation, chemicals which were considered to be distinct, have been merged into a single entry. For example, compounds which have studies using either commercial or technical grade chemicals, or the same compound at different purities, were distinct entries with different unique identifiers in the CPDB. Lhasa has considered these studies as being related to the same chemical, and so has recorded the information in a single entry, with the relevant information about grade/purity added. Therefore there are currently 1,529 compounds in the Lhasa Carcinogenicity Database, with 6,529 related studies.

Lhasa TD50

One of the key uses of the CPDB is to provide a numerical description of carcinogenicity potency (TD50), estimated for each set of tumour incidence data reported in the CPDB. The Gold TD50 provides a “standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis”. To find out more about the CPDB TD50 and how it has been calculated, please visit the TOXNET webpage.

Lhasa Limited has calculated its own TD50 values based on the same data used for the Gold TD50. Both values will be available in the Lhasa Limited Carcinogenicity database, and a paper will be published in the near future describing the methodology used by Lhasa’s scientists.

The Future

Lhasa Limited intends to continue maintaining the Carcinogenicity Database by searching the literature, gathering studies and compounds, and estimating the Lhasa TD50. Lhasa Limited intends to keep this resource online and freely available for the foreseeable future.

Features and Benefits 

  • Structure searchable – The ability to easily build complex queries around both structures and associated data, which allows for the retrieval of specific information, aiding decision support and improving productivity.
  • Freely available online – There is no need to install the database, it can be easily accessed online at any time.
  • Lhasa TD50 provided – Lhasa Limited has created its own TD50 from the data, based on Gold’s methods. Both the Lhasa TD50 and Gold TD50 will be provided.
  • Regular maintenance – Both the software and the data will be updated regularly to ensure it stays current.
  • Attractive user interface – The redesigned user interface is clear, intuitive and easy to use.

 

Key References 

Peto, R., Pike, M.C., Bernstein, L., Gold, L.S., and Ames, B.N.; ‘The TD50: A proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments’; Environmental Health Perspectives; 58: 1-8; (1984).

 

Sawyer, C., Peto, R., Bernstein, L., and Pike, M.C.; ‘Calculation of carcinogenic potency from long-term animal carcinogenesis experiments’; Biometrics; 40: 27-40; (1984).

 

Contact Us

© 2017 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

QuestionPro supports sample survey questions such as multiple choice, drop-down menu, likert-scale, semantic differential, matrix, constant sum, drag-and-drop, slider-scale, net-promoter scale, and many more question types.